Tacrolimus Market RegionalAnalysis
North America TacrolimusMarket is expected to dominate over the forecast period. Presence ofleading manufacturers as well as high number of organ transplant procedures isexpected to support global tacrolimus market growth. Regional genericmanufacturers are focusing on providing generic version of tacrolimusformulations in developed as well emerging economies. For instance, StridesArcolab received the U.S. Food & Drug Administration (FDA) approval fortacrolimus capsules to be used as immuno-suppressant in 2014. Sandoz launchedTacrolimus, a generic version of Astellas’s PROGRAF (tacrolimus) in Japan, in2015. Moreover, The European Medicines Agency’s (EMA) Committee for MedicinalProducts for Human Use (CHMP) recommended granting marketing authorization fortacrolimus’ generic, Tacforius in 2017. These factors have supported the globaltacrolimus market growth.
Tacrolimus is used as animmunosuppressant mainly after organ transplant procedures to prevent organrejection. Tacrolimus inhibits the activation of serine-threonine phosphatase,calcineurin, in T lymphocytes. This suppresses T lymphocyte activation and thesubsequent generation of cytotoxic lymphocytes, thereby suppressing processesleading to organ rejection. Tacrolimus is primary immunosuppression drug usedin kidney and liver transplant patients. Organ transplanted patients oftenrequire lifelong treatment with immunosuppressant. Major applications of thisincludes in cardiac transplant rejection, liver transplant rejection, kidneytransplant rejection, and lung transplant immunosuppression treatment.Tacrolimus is available in various dosage forms such as tablets, capsules, andinjections.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2298
Tacrolimus Market Drivers
Tacrolimus is majorly used as animmunosuppressant after organ transplant procedures. Advancement in organtransplant procedures is a major factor expected to increase the number oforgan transplants, which in turn is expected to boost global tacrolimus marketgrowth over the forecast period. For instance, new methods are being researchedto match more donor organs with patients such as stem cell studies, trophicfactor studies, and natural models. As the need for organ transplantationincreases and the waiting list continues to grow, successful utilization andtransplantation of as many available donor organs as possible has becomeimportant. According to Organ Procurement and Transplantation Network (OPTN)117,000+ number of men, women, and children are on the national transplantwaiting list as of July 2017 in the U.S. and 17,155 organ transplants are doneso far in 2017.
Moreover, according to NationalKidney Foundation as of 2016, 121,678 people are waiting for lifesaving organtransplants in the U.S., of which 100,791 people are waiting for kidneytransplants. Moreover, organ transplantation procedures have evolved withincrease in feasibility and better understanding of immunology, which has allowedfor improved matching rates for organs and patients after transplants. This isexpected to result in increasing number of organ transplants which is expectedto support the global tacrolimus market growth over the forecast period.
Browse Research Report:https://www.coherentmarketinsights.com/ongoing-insight/tacrolimus-market-2298
Certain side effects (malignancy,Psychosis, and others) of tacrolimus, although not significant, may hamper theglobal tacrolimus market growth. However, major growth limiting factor isexpected to be significant gap between demand and supply of transplant organs,which indirectly could affect the global tacrolimus market growth.
Tacrolimus Market Key Players
Key players operating in theglobal tacrolimus market include GlaxoSmithKline Plc, Abbott Laboratories,Novartis International AG, Mylan N.V., Astellas Pharma, Inc., TakedaPharmaceuticals Company Ltd, Senju Pharmaceutical Co. Ltd., GuikePharmaceutical Co. Ltd., DR. Reddy’s Laboratories Ltd., and GlenmarkPharmaceuticals Ltd.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2298
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
